There have been no recommendations for revaccination with the Japanese encephalitis (JE) vaccine in post-hematopoietic stem cell transplantation (HSCT) patients. This study aimed to measure the immunogenic response to a live-attenuated JE vaccine (SA 14-14-2) in post-HSCT patients. JE-specific neutralizing Ab titers were measured before and after the JE vaccination. The patients with Ab titers o 10 at the 3-month time point received a second injection at 6 months. A total of 28 patients (male:female = 11:17) with a median age of 13 years (4-21 years) were included. The underlying diseases were thalassemia (50%) and hematologic malignancies (50%). Ten patients (35.7%) had Ab titers above the preventive level before vaccination. Nine of 18 patients (50%) seroconverted at 3 months after a single JE vaccination, but only three of these patients had sustained protective Ab levels. Seven of nine patients (78%) seroconverted at 3 months after a second JE vaccine injection, and all of these patients sustained protective Ab levels at 12 months. In conclusion, post-HSCT patients had low seroconversion rates after a single dose of the live-attenuated JE vaccine. These patients may require at least two doses of the JE vaccine to ensure protective Ab levels.
INTRODUCTION
Japanese encephalitis (JE) virus is the most common cause of viral encephalitis in Asia and the western Pacific.
1,2 JE is a severe neurological disease with no specific treatment. Approximately half of the patients with JE suffer from long-term neurological deficits or death. 3 Immunization against JE virus is the most effective strategy for preventing JE infection. After the JE immunization program was implemented in Nepal, the incidence of JE was dramatically decreased. 4 JE immunization has been shown to be cost-effective in several countries. [5] [6] [7] However, the WHO reported that only 10 out of 24 countries with a JE virus transmission risk had included JE vaccines in the national immunization program. 8 Currently, there are three types of JE vaccines including inactivated mouse brain-derived, liveattenuated and inactivated Vero cell culture-derived vaccines. 8 A live-attenuated JE vaccine (SA 14-14-2) was originally licensed in China and has been widely used in Asian countries. 9 The effectiveness of this vaccine was 80% in children receiving one dose and 97.5% in those who received two doses (1 year apart). 10 Children receiving a two-dose schedule of the vaccine, with the second dose 1 or 3 months after the first dose, had seroconversion rates of 100 and 94-100%, respectively. 11 Recently, a study on the safety and immunogenicity of the JE vaccine (SA 14-14-2) in 150 Thai infants demonstrated a seroconversion rate of 95% at 3 months after a single dose without vaccine-related serious side effects. 12 Severe adverse events such as encephalitis or meningitis were not reported in a cohort of a large number of children after the administration of the live-attenuated JE vaccine (SA14-14-2). 13 After hematopoietic stem cell transplantation (HSCT), patients lose their immunity to vaccine-preventable diseases. The Ab titers against diphtheria, tetanus, pertussis, poliovirus, measles, mumps, rubella and hepatitis B were not above the preventive ranges in most HSCT patients. 14, 15 Therefore, recommendations for vaccinations in HSCT recipients have been developed and are widely used in clinical settings. 16 However, the JE vaccine has not been included in the recommendations due to the lack of studies regarding the immunogenicity and appropriate timing of the vaccine in this special population. 16 To answer these unsolved questions, we performed a prospective cohort study to measure the immunogenicity and assess the safety of the live-attenuated JE vaccine (SA 14-14-2) in patients who had received an HSCT during childhood.
SUBJECTS AND METHODS
We enrolled patients diagnosed with benign and malignant hematologic diseases who underwent allogeneic HSCT at the Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. The patients were regularly followed up at the bone marrow transplant clinic. The inclusion criteria for the enrolled patients included a post-HSCT period of at least 2 years, the discontinuation of any immunosuppressive agents at least 6 months prior to the trial, and no evidence of acute or chronic GVHD. The calculated sample size was 26 patients. This study was approved by Ramathibodi Institutional Review Board. All parents or participants provided written informed consent or assent as appropriate in accordance with the Declaration of Helsinki.
The preparative regimen for a 6/6 HLA-matched-related HSCT for thalassemia include busulfan and cyclophosphamide. Fludarabine and anti-thymocyte globulin were added for an 8/8 HLA-matched unrelated HSCT. Patients with hematologic malignancies received cytarabine, cyclophosphamide and total body irradiation for a matched-related HSCT and anti-thymocyte globulin for an unrelated HSCT, respectively. GVHD prophylaxis consisted of cyclosporine A (CsA) and methotrexate. CsA was tapered and withdrawn within 6 months after the HSCT in patients without acute GVHD. The first-line treatment of acute GVHD was initiated with methylprednisolone or prednisolone at 2 mg/kg/day. The treatment of chronic GVHD was with CsA and prednisolone. The second-and third-line treatments of GVHD were at the discretion of the transplant physicians.
After enrollment, peripheral blood was drawn for a complete blood count, for a lymphocyte subset count and to determine neutralizing Ab titers to JE virus. Then, 0.5 ml of the JE vaccine (SA 14-14-2) was subcutaneously injected into the patients. The Ab titers were measured at 1 and 3 months after the vaccinations. If a patient had an Ab titer of 410 at the 3-month time point, the Ab titer was measured at 6 and 12 months.
If a patient had an Ab titer of o10 at the 3-month time point, a second dose of the JE vaccine was given at 6 months. Then, the Ab titer was measured at 7, 9, 12 and 18 months, that is, at 1, 3, 6 and 12 months after the second vaccination.
The parents or guardians received vaccine cards for recording the possible side effects of the vaccine for three consecutive days after the injection.
Neutralizing Abs were measured using a plaque reduction neutralization test. 17 An Ab titer 410 was considered to be protective against JE virus. JE-specific neutralizing Ab titers before and after immunization We measured JE-specific neutralizing Ab titers before the JE vaccine injection. There were 10 patients (35.7%) with protective JE Ab titers above 10. After the JE vaccination, nine patients in this group maintained JE Ab titers above 10 for 12 months. One patient lost the protective Ab level after 6 months. There were no differences in the demographic data between the patients with and without pre-existing protective Ab titers before immunization (Table 1 ). There was no statistical difference of lymphocyte subsets between these two groups ( Table 1) .
RESULTS

Demographic data
Eighteen patients had no JE-specific Abs before the JE vaccination. After the JE vaccination, nine patients (50%) seroconverted (Ab titers 410) at 3 months. However, only six of the nine patients (67%) in this group maintained the protective Ab titers at 12 months.
The nine patients who did not seroconvert by 3 months after the first JE vaccination received a second dose of the JE vaccine at the 6-month time point. Seven out of these nine patients (78%) had seroconversion 3 months after the second JE vaccination. At 12 months after the second JE vaccination, eight of the nine patients (89%) had protective JE Ab titers.
Side effects of the JE vaccine One patient developed a mild headache the day after the JE vaccination. The headache resolved after oral acetaminophen and a few hours of rest. There were no febrile episodes, allergic reactions, seizures, alterations of consciousness or clinical symptoms of encephalitis in any of the patients.
DISCUSSION
To prevent disability and death from JE virus infection, active JE immunization is the most appropriate and efficacious approach in at-risk countries. Originally, an inactivated JE-MB vaccine was produced and widely used for decades in Japan, South Korea, Taiwan and Thailand. 18 Thai children receiving two doses of the JE-MB vaccine exhibited a 100% seroconversion rate. 19 Furthermore, a study from Taiwan demonstrated that the 25-year vaccine efficacy was 95% after three doses of the JE-MB vaccine. 20 The JE-MB vaccine was associated with a common localized reaction at the injection site and mild systemic side effects. 18, 19 Severe allergic hypersensitivity reactions and adverse neurological events have been reported. 18, 19, 21 Thailand expanded the immunization program to include three doses of the JE-MB vaccine in 1990. All of the subjects in this study had already received the JE-MB vaccine before the HSCT. Therefore, we decided to use a nextgeneration JE vaccine (SA 14-14-2) available in Thailand to avoid possible severe side effects from repeated doses of the JE-MB vaccine in our study.
The seroconversion rates for producing protective antibodies after receiving routine vaccines reach nearly 100% in healthy children, whereas the response rates of re-immunizations in patients after an HSCT vary according to the types of vaccine. Inaba et al. 15 demonstrated that 490% of the studied HSCT patients were able to maintain long-term protective Ab levels for tetanus, rubella, poliovirus and diphtheria. In contrast, the longterm response rates to pertussis, measles, mumps and hepatitis B were only 25, 66.7, 61.5 and 72.9%, respectively. 15 The seroconversion rates for the live-attenuated JE vaccine (SA 14-14-2) in healthy children were 95% for both the single-dose and 2-dose Abbreviations: HSCT = hematopoietic stem cell transplantation; JE = Japanese encephalitis.
Immunogenicity of JE vaccine in post-HSCT patients S Pakakasama et al schedules. 11, 12 The protective rates of the single dose of this type of JE vaccine were 98.5 and 96.2% at 1 and 5 years after immunization, respectively. 22, 23 Our study confirmed that post-HSCT patients exhibit inferior responses to the live-attenuated JE vaccine (SA 14-14-2) compared with healthy children. Only 50% of our subjects seroconverted at 3 months after a single injection, and 67% of this group maintained the protective Ab levels at 1 year. Therefore, the single-dose schedule of the JE vaccine (SA 14-14-2) may not be suitable for post-HSCT patients. After receiving the second dose of the JE vaccine, 78% of the patients without seroconversion developed Ab titers above the protective level. The two-dose schedule of the JE vaccine (SA 14-14-2) may increase the seroconversion rate in post-HSCT patients. However, our study was not designed to demonstrate the effect of a second dose of the JE vaccine in patients with seroconversion after a single dose. Administration of a second dose in this group may enhance the Ab levels and better maintain long-term immunity to JE virus.
Re-immunization with any live-attenuated vaccine in post-HSCT patients is performed cautiously because of vaccine-associated infections such as that described in a case report of measles occurring after an measles, mumps and rubella vaccination. 24 The recommended time for an measles, mumps and rubella vaccine is 24 months after an HSCT, by which time, it is assumed that the patients would have had a satisfactory immune system recovery. 16 The safety of a live-attenuated varicella vaccine was demonstrated in patients who were at least 2 years post HSCT, were off all immunosuppressive therapy and did not have chronic GVHD. 25, 26 The side effects were mild; 3 of the 44 patients developed a skin rash within 2.5 weeks of the vaccination. 25 No severe vaccineassociated reactions were reported after the varicella vaccine injection. 25, 26 Our study carefully included a group of patients who were at least 24 months post HSCT with a low risk of immature immune recovery, had discontinued any immunosuppressive agents at least 6 months prior to the study, and were without any clinical or laboratory evidence of chronic GVHD. Our data revealed that these patients had total lymphocyte and CD4+ cell counts of 41000 and 400 cells/mm 3 , respectively. We demonstrated that there were no serious adverse reactions to the JE vaccine (SA 14-14-2) in our patients. These data suggests that the live-attenuated JE vaccine (SA 14-14-2) is safe for post-HSCT patients who meet our inclusion criteria.
In conclusion, our study showed that half of the post-HSCT patients did not produce antibodies against JE virus after a single dose of the live-attenuated JE vaccine (SA 14-14-2). Two doses of this vaccine may ensure seroconversion in most post-HSCT patients. Post-HSCT patients living in or travelling to endemic JE areas should be immunized with the JE vaccine for protection against this severely infectious disease.
